Immune cell subset profiling in multiple sclerosis after fingolimod initiation and continued treatment: The FLUENT study.

ABSTRACT:

Background

Fingolimod is a sphingosine 1-phosphate receptor modulator approved for relapsing MS. Long-term effects on the immunological profile are not fully understood.

Objective

Investigate fingolimod's temporal effects on immune cell subsets, and safety outcomes.

Methods

In FLUENT, a 12-month, prospective, non-randomized, open-label, phase IV study, adult participants received fingolimod 0.5 mg/day. Changes in immune cell subsets, anti-John Cunningham virus (JCV) antibody index, and serum neurofilament levels were assessed.

Results

165 fingolimod-naive and 217 participants treated for 2-12 years in routine clinical practice were enrolled. Levels of all monitored peripheral lymphocyte subsets were reduced from month 3 in fingolimod-naive participants. Greates

SUBMITTER: Mao-Draayer Y 

PROVIDER: S-EPMC9346260 | biostudies-literature | 2022 Jul-Sep

REPOSITORIES: biostudies-literature